Trabalho de evento-resumo periodico

Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC) (2015)

• Authors:
  • Bachelot, Thomas
  • Villanueva, Cristian
  • Royce, Melanie
  • Debled, Marc
  • Cruz, Felipe Melo
  • Hegg, Roberto
  • Brechenmacher, Thomas
  • Manlius, Corinne
  • Ringeisen, Francois
  • Cardoso, Fatima
• Autor USP: HEGG, ROBERTO - FM
• Unidade: FM
• DOI: 10.1016/S0960-9776(15)30068-0
• Subjects: NEOPLASIAS MAMÁRIAS (COMPLICAÇÕES); TERAPIAS COMPLEMENTARES; RECEPTORES HORMONAIS
• Language: Inglês
• Imprenta:
  • Publisher place: Edinburgh
  • Date published: 2015
• Source:
  • Título: The Breast
  • ISSN: 0960-9776
  • Volume/Número/Paginação/Ano: v. 24, n. supl. 3, p. S41, abst. PO56, 2015
• Conference titles: Advanced Breast Cancer Third International Consensus Conference

Informações sobre o DOI: 10.1016/S0960-9776(15)30068-0 (Fonte: oaDOI API)
• Este periódico é de acesso aberto
• Este artigo NÃO é de acesso aberto
  

---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  BACHELOT, Thomas et al. Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC). The Breast. Edinburgh: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/S0960-9776(15)30068-0. Acesso em: 24 jan. 2026. , 2015

• APA

  Bachelot, T., Villanueva, C., Royce, M., Debled, M., Cruz, F. M., Hegg, R., et al. (2015). Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC). The Breast. Edinburgh: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/S0960-9776(15)30068-0

• NLM

  Bachelot T, Villanueva C, Royce M, Debled M, Cruz FM, Hegg R, Brechenmacher T, Manlius C, Ringeisen F, Cardoso F. Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC) [Internet]. The Breast. 2015 ; 24( supl. 3): S41.[citado 2026 jan. 24 ] Available from: https://doi.org/10.1016/S0960-9776(15)30068-0

• Vancouver

  Bachelot T, Villanueva C, Royce M, Debled M, Cruz FM, Hegg R, Brechenmacher T, Manlius C, Ringeisen F, Cardoso F. Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC) [Internet]. The Breast. 2015 ; 24( supl. 3): S41.[citado 2026 jan. 24 ] Available from: https://doi.org/10.1016/S0960-9776(15)30068-0

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• Genetics of ramucirumab-associated hypertension in the ROSE/TRIO-012 breast cancer trial
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
• Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer a clinical trial
• Bolero-4: A Phase 2, Open-Label, multicenter, single-arm trial investigating the efficacy and safety of first-line everolimus (EVE) in combination with letrozole (LET) in postmenopausal patients (PTS) with estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) metastatic or locally advanced unresectable breast cancer (BC)
• Final efficacy results of the randomized phase III BEATRICE trial evaluating adjuvant bevacizumab-containing therapy in triple-negative early breast cancer
• Hormonioterapia neoadjuvante no câncer de mama
• Superexpressao do oncogene her-2/neu em carcinomas de mama: analise clinica e imunohistoquimica
• Tratamento neoadjuvante no câncer de mama
• Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)
• Terapia estrogenica e cancer de mama